How should we introduce high-dose chemotherapeutic strategies into the adjuvant management of high-risk breast cancer in Australasia?

Australian and New Zealand Journal of Surgery

Volumn 68, Issue 1, 1998, Pages 10-15

  Back, M ^a   Delaney, G ^d   Denham, J ^a   Graham, P ^d   Hamilton, C ^a   Morgan, G ^b   O'Brien, P ^a   Yulie, P ^c  

^a NEWCASTLE MATER HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c MATER HOSPITAL   (Australia)

^d Hunter Regional Mail Centre ^*

Author keywords

Breast cancer; High dose chemotherapy; Toxicity

Indexed keywords

ADJUVANT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOXANTRONE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AUSTRALIA AND NEW ZEALAND; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; FEMALE; HUMAN; METHODOLOGY; REVIEW;

EID: 0031982938     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.1998.tb04628.x     Document Type: Review

References (31)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992; 339: 71-85.
2. Basser RL. IBCSG Trial 15-95 Protocol. International Breast Cancer Study Group 1995.
3. Bonnadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N. Engl. J. Med. 1995; 332: 901-6.
4. Ung O, Langlands AO, Barraclough B, Boyages J. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. J. Clin. Oncol. 1995; 13: 435-43.
5. Bonnadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 1995; 273: 542-7.
6. Triozzi PL, Rhoades C, Thomton DE. High-dose chemotherapy for breast cancer. Cancer Treat. Rev. 1995; 21: 185-98.
7. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II node-positive breast carcinoma. N. Engl. J. Med. 1994; 330: 1253-9.
8. IBCSG. Trial 13-93 Protocol. International Breast Cancer Study Group 1993.
9. Dimitov N, Anderson S, Fisher B. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: Findings from NSABP B-22. Proc. Am. Soc. Clin. Oncol. 1994; 13: 64.
10. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous hone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol. 1993; 11: 1132-43.
11. Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: Yes. In: DeVita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology 1995. Philadelphia: JB Lippincott Company, 1995.
12. Basser RL, To LB, Begley CG et al. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Clin. Cancer Res. 1995; 1: 715-21.
13. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with haematopoietic rescue as primary treatment for metastatic breast cancer: A randomised trial. J. Clin. Oncol. 1995; 13: 2483-9.
14. Peters WP, Berry D, Vredenburgh JJ et al. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving > 10 axillary lymph nodes (Duke/CALBG 8782). Proc. Am. Soc. Clin. Oncol. 1995; 14: 317.
15. Gianni AM, Siena S, Bregni B et al. Five year results of high-dose sequential adjuvant chemotherapy in breast cancer with > 10 positive nodes. Proc. Am. Soc. Clin. Oncol. 1995; 14: 90.
16. Hortobagyi GN. Is high-dose chemotherapy an established treatment for breast cancer? Los Angeles: American Society of Clinical Oncology, 1995.
17. Pierce LJ, Glatstein E. Postmastectomy radiotherapy in the management of operable breast cancer. Cancer 1994; 74: 477-85.
18. Overgaard M, Christensen J, Johansen H et al. Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82) trial. Int. J. Radiat. Oncol. Biol. Phys. 1990; 19: 1121-4.
19. Arriagada R, Rutqvist LE, Mattsson A, Krumur A, Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J. Clin. Oncol. 1995; 13: 2869-78.
20. Cuzick J, Stewart H, Rutqvist L et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 1994; 12: 447-53.
21. Marks LB, Halperin EC, Prosnitz LR et al. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with > 10 positive axillary lymph nodes. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 1021-6.
22. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 1995; 333: 1540-5.
23. Carter DL, Marks LB, Hussein AM et al. The impact of consolidative radiotherapy in patients with 'Stage IV' breast cancer who achieve a complete response to induction chemotherapy randomised +/- high dose chemotherapy with autologous bone marrow transplant. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36 (Suppl.): 216.
24. Mundt AJ, Sibley GS, Williams S et al. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: Implications for the use of adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1994; 30: 151-60.
25. Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies: Results of the national practice in cancer of the cervix. Cancer 1983; 51: 959-67.
26. McArdle CS, Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 1991; 302: 1501-5.
27. Basser RL, Rasko JEJ, Clarke K et al. Thrombopoietic effect of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279-81.
28. Archimbaud E, Ottman O, Liu Yin JA et al. Clinical application of platelet and myeloid growth factors. Blood 1996; 88: 447a.
29. Rutqvist L, Lax I, Fornander T, Johansson H. Cardiovascular mortality in a randomised trial of adjuvant radiation therapy vs. surgery alone in primary breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 1992; 22: 887-96.
30. Curtis RE, Boice JD, Stovall M et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Engl. J. Med. 1992; 326: 1745-51.
31. Stewart J. Submission to Hunter Area Health Service: IBCSG 15-95.